ArticleInterdisciplinary cardiovascular and thoracic surgery2025
Multidisciplinary tumour boards and surgical intervention improve overall survival in patients with Stage III non-small-cell lung cancer: a retrospective cohort study.
Article in Interdisciplinary cardiovascular and thoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Task Requirements, Workflow Processes and Technological Constraints in Virtual Multidisciplinary Tumour Board Meetings: Insights for Extended Reality-Based Solutions in Thoracic Oncology.Interdisciplinary cardiovascular and thoracic surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesGiven the poor outcomes and treatment complexities in Stage III non-small-cell lung cancer (NSCLC)-especially in challenging subgroups-we aimed to assess whether a multidisciplinary tumour board (MTB) approach combined with surgical intervention could improve overall survival (OS).
methodsWe retrospectively reviewed 242 patients with Stage III NSCLC treated from January 2018 to September 2023. Patients were managed either via MTB discussions or standard care and were further categorized based on whether they underwent surgical resection.
resultsPatients whose cases were discussed in an MTB demonstrated significantly improved overall 1-, 3-, and 5-year survival across the entire Stage III cohort, with particularly pronounced benefits in the Stage IIIC subgroup. In addition, surgical intervention was associated with significantly higher OS at 1, 3 and 5 years for all Stage III patients, and these benefits were especially evident among those with Stage IIIA disease.
conclusionsOur findings suggest that both MTB discussions and surgical resection are associated with higher observed OS in Stage III NSCLC. These results support the potential clinical value of integrating multidisciplinary treatment strategies to optimize outcomes in this challenging patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.